Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018'; Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis.
It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner.
The report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018' outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 10, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal and Oncology which include indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Homozygous Familial Hypercholesterolemia (HoFH), Type 2 Diabetes, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), Liver Diseases, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH) and Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018'; Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis.
It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner.
The report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018' outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 10, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal and Oncology which include indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Homozygous Familial Hypercholesterolemia (HoFH), Type 2 Diabetes, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), Liver Diseases, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH) and Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)
- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Overview
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development
AFFiRiS AG
Betagenon AB
Biocad
Bioleaders Corp
BioLingus AG
Dicerna Pharmaceuticals Inc
Ensemble Therapeutics Corp
Innovent Biologics Inc
Kowa Co Ltd
Noxopharm Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles
AK-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-04A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-06A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CiVi-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVILM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCRPCSK-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
O-304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06446846 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PCSK9 for Hyperlipidemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-PCK9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UBP-1214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Products
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Product Development Milestones
Featured News & Press Releases
Mar 10, 2018: Praluent (alirocumab) Significantly Reduced Risk of Cardiovascular Events in High-risk Patients, and was Associated with Lower Death Rate
Mar 10, 2018: Regeneron and Sanofi Announce Plans to Make Praluent (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
Mar 08, 2018: The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule
Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
Jan 25, 2018: Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
Nov 06, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
Nov 02, 2017: Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics
Oct 05, 2017: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent (alirocumab)
Aug 28, 2017: New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017
Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Overview
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development
AFFiRiS AG
Betagenon AB
Biocad
Bioleaders Corp
BioLingus AG
Dicerna Pharmaceuticals Inc
Ensemble Therapeutics Corp
Innovent Biologics Inc
Kowa Co Ltd
Noxopharm Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles
AK-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-04A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-06A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CiVi-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVILM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCRPCSK-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
O-304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06446846 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PCSK9 for Hyperlipidemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-PCK9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UBP-1214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Products
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Product Development Milestones
Featured News & Press Releases
Mar 10, 2018: Praluent (alirocumab) Significantly Reduced Risk of Cardiovascular Events in High-risk Patients, and was Associated with Lower Death Rate
Mar 10, 2018: Regeneron and Sanofi Announce Plans to Make Praluent (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
Mar 08, 2018: The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule
Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
Jan 25, 2018: Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
Nov 06, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
Nov 02, 2017: Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics
Oct 05, 2017: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent (alirocumab)
Aug 28, 2017: New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017
Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AFFiRiS AG, H1 2018
Pipeline by Betagenon AB, H1 2018
Pipeline by Biocad, H1 2018
Pipeline by Bioleaders Corp, H1 2018
Pipeline by BioLingus AG, H1 2018
Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
Pipeline by Ensemble Therapeutics Corp, H1 2018
Pipeline by Innovent Biologics Inc, H1 2018
Pipeline by Kowa Co Ltd, H1 2018
Pipeline by Noxopharm Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Portola Pharmaceuticals Inc, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Pipeline by The Medicines Company, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AFFiRiS AG, H1 2018
Pipeline by Betagenon AB, H1 2018
Pipeline by Biocad, H1 2018
Pipeline by Bioleaders Corp, H1 2018
Pipeline by BioLingus AG, H1 2018
Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
Pipeline by Ensemble Therapeutics Corp, H1 2018
Pipeline by Innovent Biologics Inc, H1 2018
Pipeline by Kowa Co Ltd, H1 2018
Pipeline by Noxopharm Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Portola Pharmaceuticals Inc, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Pipeline by The Medicines Company, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AFFiRiS AG
Betagenon AB
Biocad
Bioleaders Corp
BioLingus AG
Dicerna Pharmaceuticals Inc
Ensemble Therapeutics Corp
Innovent Biologics Inc
Kowa Co Ltd
Noxopharm Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AFFiRiS AG
Betagenon AB
Biocad
Bioleaders Corp
BioLingus AG
Dicerna Pharmaceuticals Inc
Ensemble Therapeutics Corp
Innovent Biologics Inc
Kowa Co Ltd
Noxopharm Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company
